Identification of linear epitopes in SjSP-13 of Schistosoma japonicum using a GST-peptide fusion protein microplate array

Li Ma1†, Wenrong Zhao1†, Xunya Hou2, Mengmeng Liu1, Yanna Li1, Li Shen1 and Xindong Xu1*

Abstract
Background: The identification and characterization of epitopes facilitate the discovery and development of new therapeutics, vaccines and diagnostics for infectious diseases. In this study, we developed a glutathione S-transferase (GST)-peptide fusion protein microplate array for the identification of linear B-cell epitopes and applied this novel method to the identification of linear B-cell epitopes of SjSP-13, an immunodiagnostic biomarker of schistosomiasis japonica.

Methods: SjSP-13 was divided into 17 overlapped peptides (p1-17), and the coding sequence of each peptide was obtained by annealing two complementary oligonucleotides. SjSP-13 peptides were expressed by fusion with an N-terminal GST tag and a C-terminal 6xHis tag. The GST-peptide-His fusion protein was specifically bound to the Immobilizer Glutathione MicroWell 96-well plates without purification. SjSP-13 peptides and core epitopes that could be recognized by sera from schistosomiasis patients were identified by ELISA and confirmed by Western blot analysis. The receiver operating characteristic (ROC) analysis was performed to determine the diagnostic validity of the identified peptide.

Results: Full-length GST-peptide-His fusion proteins were successfully expressed and specifically bound to the Immobilizer Glutathione MicroWell 96-well plates. Two adjacent peptides (p7 and p8) were found to be highly immunogenic in humans. The core epitope of p7 and p8 is an 11-aa peptide (80KCLDVTDNLPE90) and an 8-aa peptide (90EKIIQFAE97), respectively. The area under the ROC curve (AUC) value of the peptide which contains the two identified epitopes is 0.947 ± 0.019. The diagnostic sensitivity and specificity of the peptide is 76.7% (95% CI: 68.8–84.5%) and 100%, respectively.

Conclusions: 90EKIIQFAE97 and 80KCLDVTDNLPE90 are the two linear epitopes of SjSP-13 recognized by patient sera, and could be potential serological markers for schistosomiasis japonica.

Keywords: Epitope, Schistosoma japonicum, Diagnosis, SjSP-13, Fusion protein

Schistosomiasis is an important neglected tropical disease (NTD), which remains a serious public health problem in the tropics and subtropics with more than 230 million people infected in 78 countries [1, 2]. There are three major schistosome species that infect humans: Schistosoma japonicum, S. mansoni and S. haematobium. Of the three species, S. japonicum which is mainly found in China, the Philippines and small pockets of Indonesia, is recognized as the most difficult to control because of its zoonotic nature [3, 4]. The implementation of the new integrated strategy with emphasis on control of the infection source across China since 2004 has greatly reduced S. japonicum in humans, livestock, and intermediate host Oncomelania hupensis snails. It has been estimated that there were more than 38,000 cases of schistosome infections in 2017. Moreover, the control of schistosomiasis...
in China is particularly challenging due to the wide distribution of its snail hosts and the wide range of domestic and wild mammals that act as reservoirs for human infection. Thus, schistosomiasis remains one of the most important public health problems in China.

The scarcity of an effective diagnostic method is one of the factors that contribute to the prevalence of schistosomiasis [5]. Additionally, the current schistosomiasis elimination plan in China highlights the importance of the development of sensitive diagnostic techniques as the treatment of targeted populations is a major strategy [6]. However, the sensitivity of traditional parasitological methods, such as stool examination, is poor in low endemic areas [7, 8]. Immunodiagnostic techniques are promising tools for detecting mild-to-moderate infections. However, the currently available immunodiagnostic assays have low specificity because of the use of crude antigens, such as soluble egg antigens (SEA) consisting thousands of parasite antigens, presenting a wide cross-reaction with antigens from other worms [9, 10]. Thus, it is a prerequisite to select diagnostic biomarkers with high sensitivity and specificity.

Recently, several novel proteins with high immunogenicity were identified via immunomics [11–13], including SjSP-13, an immunodiagnostic marker of schistosomiasis japonica [14]. SjSP-13 is a member of a multigene family of saposin-like proteins, which contains the SAP-B domain that is characterized by six cysteine residues forming disulfide bonds to stabilize its structure [15]. In S. japonicum, this multigene family is present in the form of 15 members (SjSAPLP1 (SjSP-13) to SjSAPLP15) [16]. These proteins exhibit a potent lytic activity on human erythrocytes and peripheral blood mononuclear cells. Like SjSP-13, SjSAPLP4, and SjSAPLP5 are candidate diagnostic markers for schistosomiasis japonica [16]. SjSP-13 is highly expressed in young worms and adult worms but poorly expressed in eggs [17]. In adult worms, SjSP-13 is abundantly distributed on the surface and lumen of the esophageal and intestinal tracts [16]. In addition, SmSP-13, the homologous gene of SjSP-13 in S. mansoni, has been found in worm vomitus [18]. However, the epitope of this immunodominant antigen is still unclear.

In this study, we developed a novel GST-peptide fusion protein microplate array for mapping the linear B-cell epitopes. The epitopes of SjSP-13 were identified by this technology.

**Methods**

**Peptide mapping**

SjSP-13 protein contains 177 amino acids (aa), of which 21 aa at the N-terminal are predicted to be a signal peptide. We divided a 156-aa length SjSP-13 fragment without the signal peptide into 17 peptides with a length of 18 aa per peptide, except for the last 12-aa long peptide. There were 9 overlapped amino acids between the two adjacent peptides. The coding DNA sequences of each peptide were obtained by annealing two single-stranded oligonucleotides with complementary sequences. BamHI and Xhol sticky terminals were added in the upstream and downstream oligonucleotides, respectively. The resulting DNA fragments were inserted into a pGEX-His vector. The GST-peptide-His tag fusion protein was expressed in the E. coli BL21 strain with 1mM Isopropyl-D-1-thiogalactopyranoside (IPTG) induction. Cells were lysed by B-Per (Pierce, Rockford, USA) and treated with the recommended concentration of DNase, RNase and PMSE. The whole E. coli lysate without centrifugation was directly dissolved in 8M urea overnight at room temperature. After centrifugation, proteins in supernatant were renatured in refolding buffer (1.0 mM TCEP, 250 mM NaCl, 12.5 mM β-cyclodextrin, 50 mM Tris-HCl, pH 8.5). The refolded proteins were stored at −20 °C until use.

**Western blot**

Proteins were separated by SDS-PAGE and then transferred onto a nitrocellulose membrane. Western blot was performed using anti-GST tags (Abmart, Shanghai, China), anti-6xHis tags (Abmart) and schistosomiasis patient serum as the primary antibodies. Anti-mouse (Promega, Madison, USA) and anti-human (Promega) IgG horseradish peroxidase (HRP)-linked whole antibodies were used as the secondary antibodies. The ECL-PLUS system (Pierce) was used for detection according to the manufacturer’s instructions.

**Serum collection and adsorption**

Ninety-seven infected human serum samples were collected from villagers living in schistosomiasis-endemic areas who were diagnosed as schistosomiasis patients using the Kato-Katz method [19]. The egg counts of these patients ranged from 8 to 320 fecal eggs per gram (epg). The sera of healthy humans were used as controls.

Seven infected sera with high antibody titres to SjSP-13 and three control sera were selected for epitope screening. Sera were incubated with E. coli extracts and the GST protein to remove the corresponding antibodies before use. A mixture of 1 ml human serum, 5 ml bacterial lysate, 0.1 ml GST bound glutathione sepharose 4B beads and 3.9 ml PBS (pH 7.4) was rocked for 5 h at room temperature. After centrifugation, absorbed serum was stored at −20 °C until use.

**Preparation of GST-peptide-His fusion protein microplate array**

The refolded GST-peptide-His fusion proteins were diluted in PBS with a final concentration of 50–100 μg/ml.
Immobilizer Glutathione MicroWell plates (Nunc, Denmark) were coated with 100 μl/well of fusion protein solution overnight at 4 °C. Recombinant GST-His solution, E. coli lysate and PBS were set as positive, negative and blank controls, respectively. To remove the unbound proteins, the plates were washed five times with 150 mM PBS containing 0.05% Tween-20 (PBST) and blocked with PBST plus 5% skim milk powder overnight at 4 °C. After washing five times, the 96-well microplate bound GST-peptide-His fusion protein was sealed and stored at −20 °C before use.

To ensure the integrity of the bound GST-peptide-His fusion protein on the 96-well microplates, 100 μl of 1:2,000 diluted anti-GST and anti-6xHis tag were added to each well of the microplate for 1 h incubation at 37 °C. After washing for five times, 100 μl of 1:20,000 diluted HRP conjugated anti-mouse IgG secondary antibody (Promega) was added to wells for a further 1-h incubation at 37 °C. Wells were washed five times before 100 μl of SuperSignal ELISA Femto Maximum Sensitivity Substrate (Pierce) was added. The bound antibodies were quantified by measuring the relative light units (RLUs) at 425 nm with a luminometer between 1–5 min after adding the substrate (Molecular Devices, San Jose, USA).

B-cell linear epitope identification
The B-cell linear epitopes of SjSP-13 were identified by ELISA using the 96-well microplate bound GST-peptide-His fusion protein. The 1:100 diluted adsorbed human sera were added to the microplate and 1:20,000 diluted HRP conjugated anti-human IgG secondary antibody (Promega) was added as the detecting antibody. The ratio of RLUs of a human serum sample to GST-peptide-His fusion protein was calculated using the formula: R = (RLUs of GST-peptide-His fusion protein − RLUs of PBS) / (RLUs of GST-His − RLUs of PBS), and a positive reaction was considered when R ≥ 2. The screened epitopes were further verified by Western blot.

Structure prediction
Swiss-model structure online analysis software was used to simulate the three-dimensional structure model of SjSP-13 protein and the highest score was selected as the alignment template [20]. PyMOL software was then used for analyzing the positional structure of the epitope on the SjSP-13 protein [21].

ELISA
SjSP-13-based ELISA was performed as described previously [22]. Peptide-based ELISA was performed on synthesized peptides (Sangon Biotech, Shanghai, China) consisting of the two adjacent epitopes identified in this study. Polystyrene 96-well microtiter plates (Nunc, Roskilde, Denmark) were coated with peptide (5 μg per ml in coating buffer; 100 μl per well) overnight at 4 °C. Wells were blocked with PBST containing 5% non-fat milk (PBST-milk) for 2 h at 37 °C. Serum samples were diluted in 1:50 with blocking buffer and incubated for 1 h at 37 °C. HRP-conjugated goat anti-human IgG (Promega) was used to detect antibodies bound to peptide. Enzymatic reactions were developed by adding 100 μl TMB substrate to each well and terminated by stop reagent (50 μl 2 N H2SO4 per well). Absorbance values were measured at 450 nm. ELISA readings were done in duplicates.

Data analysis
Heat maps were performed with R statistical software. OD450 nm value was expressed as the mean ± standard error. The differences of OD450 nm between groups were analyzed by Student’s t-test. The diagnostic accuracy was evaluated by receiver operating characteristic (ROC) curve analysis. The area under the ROC curve (AUC) was calculated to assess the overall diagnostic performance. The sensitivity and specificity of various diagnostic tools were compared by chi-square test or Fisher’s exact test. A P-value < 0.05 was considered statistically significant.

Results
SjSP-13 peptide library construction
A 156-aa length SjSP-13 without signal peptide was divided into 16 18-aa length peptides and a 12-aa length peptide, namely p1 to p17. There are 9 overlapped amino acids between the two adjacent peptides (Fig. 1). The coding DNA sequences of each peptide were cloned into a pGEX-His vector, a modified GST fusion protein expression vector with an additional C-terminal 6xHis tag (see Additional file 1: Figure S1a). The full-length expression of GST-peptide-His fusion protein was confirmed by Western blot with anti-GST and anti-His mAb (see Additional file 1: Figure S1b). Since most of the fusion proteins are expressed as inclusion bodies, we directly dissolved the E. coli lysate in 8 M urea and then obtained soluble fusion proteins by dilution in protein refolding buffer.

Construction of GST-peptide-His fusion protein microplate array
We developed a GST fusion protein-based rapid B-cell linear epitope screening method (Fig. 2a). GST-peptide-His fusion protein was bound to the GSH-immobilized microplates via the interaction of GST and GSH. The binding fusion proteins were detected by anti-GST mAb and the integrity of fusion proteins was detected by anti-His tag mAb. As shown in Fig. 2b, the relative light units (RLUs) of all the refolded GST-peptide-His fusion proteins are significantly higher than those of the E. coli lysate control.
indicating that the fusion proteins successfully refolded and the proteins bound on the plates were full-length.

**Screening SjSP-13 peptide recognized by schistosomiasis patient sera**

The interaction between SjSP-13 peptides and schistosomiasis patient serum samples was evaluated by chemiluminescent ELISA. For initial screening of the 17 SjSP-13 peptides, we used ten serum samples from seven infected individuals and three uninfected individuals as controls. The result indicates that p8 could be recognized by 6 serum samples from Patients 1, 2, 3, 4, 5 and 7, and p7 could be recognized by 2 serum samples from Patients 2 and 6. None of the 17 SjSP-13 peptides react to the uninfected serum (Fig. 3a). We then selected representative serum samples of Patient 1, 2 and 7 for verification by Western blot. The results are consistent with ELISA (Fig. 3b).

**Identification of SjSP-13 B-cell linear core epitope**

We defined the core epitope in p7 and p8 using a panel of truncated peptides spanning the region of p7 and p8 by chemiluminescent ELISA as above (Fig. 4). For p8, progressive truncation of the peptide resulted in loss of binding effect to antibody when the peptide lost E90 at the N-terminal and E97 at the C-terminal. Therefore, the core epitope of p8 is an 8-aa peptide EKIIQFAE, spanning positions E90 to E97 (Fig. 4a). For p7, truncated peptides lose the binding effect when K80 at the N-terminal and E90 at the C-terminal are removed. The sequence of p8 core epitope spans K80 to E90, an 11-aa peptide KCLD-VTDNLPE (Fig. 4b).

**Three-dimensional visualization of immunogenic epitopes**

The three-dimensional structure of the SjSP-13 protein was predicted by a Swiss-model server. The alignment template SMTL ID was 5f92.A.
Sphingomyelin phosphodiesterase, which is a 2-subunit lipase; the smaller subunit is a member of the saposin-like (SAPLIP) proteins and the larger subunit is a GDSL lipase. The alignment modeling sequence of SjSP-13 was from K50 to K133. It is predicted that five amino acid residues (IQFAE) of the epitope 90EKIIQFAE97 are located on the exposed random crimp segment and the other three in an α-helix, while the whole sequence of epitope 80KCLDVTDNLPE90 is located in an α-helix (Fig. 5).

**Diagnostic validity of SjSP-13 peptide**

A 27-aa SjSP-13 peptide (EWKNKCLDVTDNLPEKIIQFAEHMNIL) which contains the two adjacent epitopes was applied for detecting schistosome infection. The specific antibody levels of the peptide in patients were significantly higher than healthy controls \( (t(89) = 13.24, \ P < 0.0001) \) (Fig. 6a). The ROC analysis was performed to determine the diagnostic validity of the peptide. As shown in Fig. 6b, the AUC value of the peptide is 0.947 ± 0.019. We defined the cut-off value as 2.1 times the mean OD\(_{450 \text{ nm}}\) value of the healthy control serum. The diagnostic sensitivity and specificity of the peptide is 76.7% (95% CI: 68.8–84.5%) and 100%, respectively (Table 1). We also performed SjSP-13 ELISA using sera from the same cohort (Fig. 6c). The AUC value of SjSP-13 is 0.995 ± 0.002 (Fig. 6d). The sensitivity of SjSP-13 [92.2% (95% CI: 86.3–98.1%)] is significantly higher than SjSP-13 peptide, but the specificity of SjSP-13 [95.6% (95% CI: 91.6–99.5%)] is slightly but not significantly lower than SjSP-13 peptide (Table 1). In addition, we examined the cross-reaction of the peptide to patients with clonorchiasis \( (n = 38) \). The OD\(_{450 \text{ nm}}\) value range was 0.022–0.058, much lower than the cut-off value (0.105). No cross-reaction was observed.

**Discussion**

The global schistosomiasis control programme has made tremendous progress in reducing the prevalence of disease and morbidity in many endemic areas mainly due to the widespread treatment with the anti-schistosome agent praziquantel. However, high reinfection rates coupled with the risk of drug resistance support the need for new interventions, such as vaccination. Previous studies have identified a highly immunogenic antigen, SjSP-13, a member of a multigene family of saposin-like proteins. This antigen could be widely recognized by serum IgG of infected humans and has been applied for immunodiagnosis of schistosomiasis [14, 22]. Due to their highly immunogenic properties, B-cell epitopes of SjSP-13 were identified in this study.

B-cell epitopes can be divided in two categories: continuous and discontinuous. Continuous or linear epitopes are made up of consecutive amino acids, whereas discontinuous or conformational epitopes constitute spatially folded amino acids. The prediction of B-cell epitopes is much more complex than the prediction of T-cell epitopes and conformational epitopes. This might be due to the reason that linear B-cell epitope possesses variable lengths, from 2 to 85 amino acids, compared to the almost fixed length core of T-cell epitopes [23]. This variability imposes several obstacles for algorithm developers. The core sequence linear epitope is commonly shorter than the predicted peptide and should be verified experimentally by truncated or residue substitution peptides. Such experimental methods for identification of B-cell epitopes are costly and time-consuming.

Here, we developed a GST-peptide fusion protein microplate array, in which each peptide was expressed with a C-terminal GST tag and an N-terminal 6xHis tag, and then arrayed in GSH-immobilized plates through the interaction of GST with its substrate glutathione. The binding amount and integrity of fusion proteins could be assessed by anti-GST and anti-6xHis tag Abs.
This technique was much more economical compared to identifying epitopes by synthetic peptides, as the cost of synthesized oligonucleotides is cheaper. Unlike synthetic peptides, the peptides in the form of a GST fusion protein could be easily verified by Western blot analysis. In addition, the GST-peptide fusion proteins can be used in other experiments, such as GST pull-down. In this study, we divided SjSP-13 into 17 peptides with nine overlapped amino acids between the two adjacent peptides. Two peptides, p7 and p8, could be recognized by schistosomiasis patient sera specifically.

We further determined the core epitopes of these two peptides. The core epitope of p7 is an 11-aa peptide, $\text{SGDVTDLNPE}_9$, and that of p8 is an 8-aa peptide,

![Fig. 3](image-url) Identification of SjSP-13 peptides recognized in sera from schistosomiasis patients. (a) Reaction of 10 human serum samples (seven infected samples and three uninfected samples from healthy individuals) to the 17 GST-peptide-His fusion proteins determined by chemiluminescent ELISA. $R = (\text{RLUs of GST-peptide-His} - \text{RLUs of PBS}) / (\text{RLUs of GST-His} - \text{RLUs of PBS})$. GST-peptide-His with $R \geq 2$ were considered as seropositive reaction. Abbreviations: RLUs, relative light units; HA, hemagglutinin tag-GST fusion protein. (b) The recognition of p7 and p8 by the representative serum samples of Patients 1, 2 and 7 was confirmed by Western blot.
Interestingly, these two epitopes consist of predominantly hydrophobic residues in the center flanked by charged amino acids, consistent with general B-cell epitopes [24]. The two core epitopes are adjacent to the SjSP-13 primary structure, with an overlapped residue E90. 90EKIIQFAE97 is a loop surface epitope, while 80KCLDVTDNLPE90 is an α-helix surface epitope. We observed 90EKIIQFAE97 could be recognized by six out of seven patients’ sera, while only two patients’ sera interacted with 80KCLDVTDNLPE90. The creation of bends and flexibility of 90EKIIQFAE97 might be responsible for more efficient presentation and recognition than 80KCLDVTDNLPE90 in human immune cells.

We also compared the diagnostic performance of a peptide containing the two adjacent epitopes with SjSP-13 recombinant protein. Although peptide-ELISA has a 100% of specificity, the sensitivity is reduced 15.5% when compared with SjSP-13. The finding of the SjSP-13-positive but peptide-negative patients indicates that some epitopes were missed in our screening study. The variation of epitope recognition in different individuals may be linked to genetic polymorphisms of the human HLA class II alleles. In fact, there is evidence that the HLA alleles play crucial roles in modulation of the immune response to schistosome infection [25–27]. In addition, the polymorphism of SjSP-13 gene may be the other factor explaining the reduction of sensitivity of peptide-ELISA. The peptide sequence of the two epitopes identified in the present study was highly polymorphic according to our previous study [22].
The early diagnostic performance of SjSP-13 recombinant protein was evaluated in animal models previously [17]. SjSP-13 specific antibodies could be detected as early as 3 weeks post-infection in mouse model. However, the increase of SjSP-13 specific antibodies was not observed in rabbit model at this time point. These results indicate that, like SjSP-13 protein, SjSP-13-derived epitopes were not ideal biomarkers for detection of early *S. japonicum* infection.

**Table 1** Comparison of diagnostic validity of SjSP-13 peptide with SjSP-13 recombinant protein

| Antigen     | Patients (n = 90) | Healthy controls (n = 90) |
|-------------|------------------|--------------------------|
|             | True positive    | False negative | Sensitivity (%) (95% CI)* | True negative | False positive | Specificity (%) (95% CI) |
| Peptide     | 69               | 21           | 76.7 (68.8–84.5)           | 90            | 0             | 100 (100–100)        |
| SjSP-13     | 83               | 7            | 92.2 (86.3–98.1)           | 86            | 4             | 95.6 (91.6–99.5)     |

*χ² = 8.289, df = 1, P = 0.004 when compared by a chi-square test

**Fig. 6** Comparison of the diagnostic performance of peptide-ELISA and SjSP-13-ELISA. The specific antibody to peptide (a) and SjSP-13 (c) in patients (n = 90) and healthy controls (n = 90) were evaluated by ELISA. ROC analysis was performed for peptide (b) and SjSP-13 (d). Data were compared using a Student’s t-test

**Conclusions**

This study identified two linear B-cell epitopes of SjSP-13, an immunodominant antigen of *S. japonicum* via a novel linear B-cell epitope screening method based on a GST-peptide fusion protein microplate array. The high immunogenicity of the two epitopes of SjSP-13 in humans makes them promising candidates for diagnosis of schistosomiasis japonica.
**Supplementary information**

**Supplementary information** accompanies this paper at https://doi.org/10.1186/s13071-019-3767-2.

**Additional file 1: Figure S1.** Construction of GST-peptide-fusion proteins. **a** The coding sequence of each peptide was obtained by annealing two complementary oligonucleotides and cloned into a pGEX-His vector for fusion and expression with an N-terminal GST tag and a C-terminal 6× His tag. **b** The expression of GST-peptide-His fusion proteins was confirmed by Western blot with anti-GST and anti-6× His antibodies.

**Abbreviations**

GST: glutathione S-transferase; GSH: glutathione; SJ:SAPLP1: *Schistosoma japonicum* saposin-like protein 1; ELISA: enzyme-linked immunosorbent assay; ROC: receiver operating characteristic; AUC: area under curve; RLU: relative light unit.

**Acknowledgements**

We thank Dr Weiqing Pan at The Second Military Medical University for his comments and discussion.

**Authors’ contributions**

LM and XX conceived and designed the study. LM, WZ, ML, YL and XX performed the experiments and analyzed the data. LM, XH, LS and XX wrote the manuscript. All authors read and approved the final manuscript.

**Funding**

This study was supported by the National Natural Science Foundation of China (Grant No. 81601782) and the Fundamental Research Funds for the Central Universities (Grant No. 2211820180544).

**Availability of data and materials**

The data that support the findings of this study are included within the article and its additional file.

**Ethics approval and consent to participate**

All study procedures were performed in accordance with and by approval of the internal review board of Tongji University School of Medicine.

**Consent for publication**

Not applicable.

**Competing interests**

The authors declare that they have no competing interests.

**Author details**

1 Research Center for Translational Medicine, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China. 2 Hunan Institute of Parasitic Diseases, Yueyang, China.

**Received:** 8 August 2019  **Accepted:** 23 October 2019  **Published online:** 30 October 2019

**References**

1. Colley DG, Bustinduy AL, Secor E, King CH. Human schistosomiasis. Lancet. 2014;383:2253–64.
2. Savio Li, Albiono C, Colley DG, Correa-Oliveira R, Fenwick A, Green W, et al. Building a global schistosomiasis alliance: an opportunity to join forces to fight inequality and rural poverty. Infect Dis Poverty. 2017;6:65.
3. Ross AG, Olveda RM, Acosta L, Harn DA, Chy D, Li Y, et al. Road to the elimination of schistosomiasis from Asia: the journey is far from over. Microbes Infect. 2013;15:858–65.
4. You H, Cai P, Tebeje BM, Li Y, McManus DP. Schistosome vaccines for domestic animals. Trop Med Infect Dis. 2018;3:68.
5. Utzinger J, Becker SL, van Lieshout L, van Dam GJ, Knopp S. New diagnostic tools in schistosomiasis. Clin Microbiol Infect. 2015;21:529–42.
6. Bergquist R, Zhou XN, Rollinson D, Reinhard-Rupp J, Kliche K. Elimination of schistosomiasis: the tools required. Infect Dis Poverty. 2017;6:138.
7. Liu DD, Liu JX, Liu YM, Hu F, Zhang YY, Xu JH, et al. Routine Kato–Katz technique underestimates the prevalence of *Schistosoma japonicum*: a case study in an endemic area of the People’s Republic of China. Parasitol Int. 2008;57:281–6.
8. Deng Y, Qiu C, Ding H, Lu DB. The ratio of the seroprevalence to the egg-positive prevalence of *Schistosoma japonicum* in China: a meta-analysis. BMC Infect Dis. 2018;18:404.
9. Zhou YB, Yang MX, Tao P, Jiang QL, Zhao GM, Wei JG, et al. A longitudinal study of comparison of the Kato–Katz technique and indirect hemagglutination assay (IHA) for the detection of schistosomiasis japonica in China, 2001–2006. Acta Trop. 2008;107:251–4.
10. Yu JM, de Vlas SJ, Jiang QW, Gryseels B. Comparison of the Kato–Katz technique, hatching test and indirect hemagglutination assay (IHA) for the diagnosis of *Schistosoma japonicum* infection in China. Parasitol Int. 2007;56:45–9.
11. Sotillo J, Doalan D, Loukas A. Recent advances in proteomic applications for schistosomiasis research: potential clinical impact. Expert Rev Proteomic. 2017;14:171–83.
12. Driguez P, Li Y, Gaze S, Pearson MS, Nakajima R, Trieu A, et al. Antibody signatures reflect different disease pathologies in patients with schistosomiasis due to *Schistosoma japonicum*. J Infect Dis. 2016;213:122–30.
13. Pearson MS, Becker L, Driguez P, Young ND, Gaze S, Mendes T, et al. Of monkeys and men: immunometric profiling of sera from humans and non-human primates resistant to schistosomiasis reveals novel potential vaccine candidates. Front Immunol. 2015;6:213.
14. Xu X, Zhang Y, Lin D, Zhang J, Xu J, Liu YM, et al. Serodiagnosis of *Schistosoma japonicum* infection: genome-wide identification of a protein marker, and assessment of its diagnostic validity in a field study in China. Lancet Infect Dis. 2014;14:889–97.
15. Don TA, Bethony JM, Loukas A. Saposin-like proteins are expressed in the gastoderm of *Schistosoma mansoni* and are immunogenic in natural infections. Int J Infect Dis. 2008;12:e39–47.
16. Liu S, Zhou X, Piao X, Hou N, Shen Y, Zou Y, et al. Saposin-like proteins, a multigene family of schistosoma species, are biomarkers for the immunodiagnosis of *Schistosomiasis japonica*. J Infect Dis. 2016;214:1225–34.
17. Zhang YB, Zhao J, Wang XY, Xu XD, Pan WQ. Evaluation of six novel antigens as potential biomarkers for the early immunodiagnosis of schistosomiasis japonica. Parasit Vectors. 2015;8:447.
18. Hall SL, Braschi S, Truscott M, Matheson W, Cesari IM, Wilson RA. Insights into blood feeding by schistosomes from a proteomic analysis of worm vomitus. Mol Biochem Parasitol. 2011;179:18–29.
19. Xie SY, Yuan M, Ji MJ, Hu F, Li ZJ, Liu YM, et al. Immune responses result in misdiagnosis of *Schistosoma japonicum* by immunodiagnosis kits in egg-positive patients living in a low schistosomiasis transmission area of China. Parasit Vectors. 2014;7:195.
20. Biasini M, Bienert S, Waterhouse A, Arnold K, Studer G, Schmidt T, et al. SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res. 2014;42:W252–8.
21. Yuan SG, Chen HCS, Filipek S, Vogel H. PyMOL and inkscape bridge the data and the data visualization. Structure. 2016;24:2041–2.
22. Xu X, Cui X, Zhu L, Li Z, Zhang Y, Ma L, et al. Effects of polymorphisms in the SJP-13 gene of *Schistosoma japonicum* on its diagnostic efficacy and immunogenicity. Front Microbiol. 2018;9:1695.
23. Singh H, Ansari HR, Raghava GPS. Predictive epitope mapping using antigen’s primary sequence. PLoS ONE. 2013;8:e62216.
24. Kringelum JV, Nielsen M, Padkjaer SB, Lund O. Structural analysis of B-cell epitopes in antibody protein complexes. Mol Immunol. 2013;53:24–34.
25. Huy NT, Hamada M, Kikuchi M, Nguyen TPL, Yasunami M, Zamora J, et al. Association of HLA and post-schistosomal hepatic disorder: a systematic review and meta-analysis. Parasitol Int. 2011;60:347–56.
hepatosplenic schistosomiasis in a Chinese population. Int J Parasitol. 2001;31:674–80.

27. Waine GJ, Ross AGP, Williams GM, Sleigh AC, McManus DP. HLA Class II antigens are associated with resistance or susceptibility to hepatosplenic disease in a Chinese population infected with Schistosoma japonicum. Int J Parasitol. 1998;28:537–42.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.